Eledon Pharmaceuticals, Inc. (ELDN): auditor change — Eledon Pharmaceuticals dismisses Crowe LLP, appoints Deloitte as auditor

Eledon Pharmaceuticals, Inc.

Audit Committee dismissed Crowe LLP as independent auditor effective April 1, 2025.
No disagreements or reportable events in fiscal years 2023 and 2024 or interim period.
Crowe's audit reports for 2023 and 2024 were unqualified and not modified.
Deloitte & Touche LLP appointed as new auditor for fiscal year ending Dec 31, 2025.

item 4.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Eledon Pharmaceuticals, Inc. dismissed Crowe LLP as its auditor.

Action: dismissal
Auditor: Crowe LLP
Successor: Deloitte & Touche LLP

Exact text from the filing

The Audit Committee of the Board of Directors (the “Audit Committee”) of Eledon Pharmaceuticals, Inc. (the “Company”) approved the dismissal of Crowe LLP (“Crowe”) as the Company’s independent registered public accounting firm and dismissed Crowe on April 1, 2025.

View on SEC.gov

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Eledon Pharmaceuticals, Inc. engaged Deloitte & Touche LLP as its auditor.

Action: engagement
Auditor: Deloitte & Touche LLP

Exact text from the filing

On April 1, 2025, the Audit Committee approved the engagement of Deloitte & Touche LLP (“Deloitte”) as its new independent registered public accounting firm for the Company’s fiscal year ending December 31, 2025 and related interim periods.

View on SEC.gov

Browse all auditor changes →

Eledon Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-25-051663

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.